Malaria caused by Plasmodium falciparum remains a major public health threat, especially
among children and pregnant women in Africa. An effective malaria vaccine would be a …

Abstract Development and Phase 3 testing of the most advanced malaria vaccine, RTS,
S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

Controlled human malaria infection (CHMI) entails deliberate infection with malaria
parasites either by mosquito bite or by direct injection of sporozoites or parasitized …

Malaria is one of the most frequently occurring infectious diseases worldwide, with almost 1
million deaths and an estimated 243 million clinical cases annually. Several candidate …

Background Exposing healthy human volunteers to Plasmodium falciparum-infected
mosquitoes is an accepted tool to evaluate preliminary efficacy of malaria vaccines. To …

Background Significant progress has been recently achieved in the development of
Plasmodium vivax challenge infections in humans, which are essential for vaccine and drug …

There is no malaria vaccine currently available, and the most advanced candidate has
recently reported a modest 30% efficacy against clinical malaria. Although many efforts have …

The development of a vaccine against malaria has public health priority. In a controlled
setting, preliminary data on the efficacy of Plasmodium falciparum vaccine candidates can …

Chapter 1 2 mechanisms and peptide drug delivery, including cell permeability to prosecute
intracellular targets, is re-defining the term “druggability”. Beyond such convergent …